STALICLA is a fast-growing drug development biotech start-up active in the field of autism spectrum disorder (ASD) with offices in Geneva and Barcelona. Through an innovative algorithm-based platform (DEPI) STALICLA has been able to identify non-behavioral subgroups of patients with idiopathic ASD and corresponding first-in class treatment candidates, thus pioneering personalized medicines for ASD. The CEO and Management team is visioning and capitalising on data integration and agile business strategy to serve patients who live today. STALICLA has recently completed a 10 million financing round at a 40 million valuation.
STALICLA has put together a knowledgeable and experienced executive and operational team, and a world class scientific committee to guide the growth of the company. Furthermore, the company has signed collaborations with leading institutions in the field, which will provide important platforms for accelerating clinical and product development.